On Thursday, March 16, 2017, the Dow Jones Industrial Average and the S&P 500 edged 0.07% and 0.16% lower, respectively, at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.01%. Five out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, Stock-Callers.com assessed the several drugs – generic equities on Friday.
San Diego, California headquartered Neurocrine Biosciences Inc.’s stock finished Thursday’s session 4.42% lower at $45.17 with a total volume of 822,301 shares traded. Over the last one month and the previous three months, Neurocrine Biosciences’ shares have advanced 8.76% and 4.08%, respectively. Furthermore, the stock has surged 32.62% in the past one year. The Company’s shares are trading above its 50-day moving average by 5.35%. Shares of Neurocrine Biosciences, which discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the US and internationally, have a Relative Strength Index (RSI) of 53.97.
Philadelphia, Pennsylvania-based Lannett Co. Inc.’s stock fell 2.28%, to close the day at $21.45. The stock recorded a trading volume of 619,635 shares. Lannett’s shares have gained 11.66% in the past one year. The Company’s shares are trading 0.71% above its 50-day moving average. Additionally, shares of the company, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 48.16.
On Thursday, shares in South San Francisco, California-based Rigel Pharmaceuticals Inc. ended the session 0.69% lower at $2.88 with a total volume of 1.13 million shares traded. Rigel Pharma’s shares have gained 21.52% in the last one month and 11.20% in the previous three months. Furthermore, the stock has surged 37.80% in the past one year. The stock is trading 19.04% above its 50-day moving average and 6.61% above its 200-day moving average. Moreover, shares of the Company, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 61.36.
On March 09th, 2017, research firm H.C. Wainwright reiterated its ‘Buy’ rating on the Company’s stock with a decrease of the target price from $6 a share to $5 a share.
On Thursday, shares in Somerset, New Jersey headquartered Catalent Inc. recorded a trading volume of 643,484 shares. The stock ended the day 1.42% lower at $28.55. Shares of the Company, which provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products worldwide, are trading at a PE ratio of 38.32. Catalent’s stock has gained 11.52% in the last three months and 12.31% in the previous one year. The Company’s shares are trading above its 50-day and 200-day moving averages by 2.41% and 12.14%, respectively. Furthermore, Catalent’s shares have an RSI of 51.59.